Refine by
Patient Selection Technology
5 companies found
Technologybased inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
Technologybased inLexington, MASSACHUSETTS (USA)
At T2 Biosystems, our mission is to save lives and improve healthcare by empowering clinicians to get patients on the right therapy faster. We come to work every day to solve critical needs in healthcare diagnostics with innovative solutions built ...
The first direct-from-blood detection of resistance markers: The T2Resistance® Panel is designed for the direct-from-blood detection of antibiotic resistance genes associated with sepsis-causing pathogens. The Panel detects many of the ...
Technologybased inBroomfield, COLORADO (USA)
Founded in 2009, Flagship Biosciences, Inc., is a technology-driven spatial biology and biomarker services company delivering the most accurate and informative data available. We are revolutionizing biomarker analysis to improve drug development and ...
Your next pathology-based CDx starts here. With the complexity of therapies increasing, the need for a robust companion diagnostic (CDx) has never been higher. Advances in tissue analysis technologies now require a more quantitative, accurate, and ...
Technologybased inLondon, UNITED KINGDOM
Embody is a spin-out company from Imperial College London. We are a team of specialists from a variety of engineering, medical, and design backgrounds. Embody provides pre-operative planning, patient specific instruments and complex surgical ...
Technologybased inFriendswood, TEXAS (USA)
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and ...
Predicting Individual Risk of Recurrence or Metastasis: DecisionDx-Melanoma was designed to address the need for a more accurate predictor of metastatic risk in patients diagnosed with cutaneous (skin) melanoma. ...